1. Home
  2. GLUE vs CRI Comparison

GLUE vs CRI Comparison

Compare GLUE & CRI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Monte Rosa Therapeutics Inc.

GLUE

Monte Rosa Therapeutics Inc.

HOLD

Current Price

$11.80

Market Cap

1.2B

Sector

Health Care

ML Signal

HOLD

Logo Carter's Inc.

CRI

Carter's Inc.

HOLD

Current Price

$31.09

Market Cap

1.5B

ML Signal

HOLD

Company Overview

Basic Information
Metric
GLUE
CRI
Founded
2019
1865
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Apparel
Sector
Health Care
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
1.2B
1.5B
IPO Year
2021
2002

Fundamental Metrics

Financial Performance
Metric
GLUE
CRI
Price
$11.80
$31.09
Analyst Decision
Strong Buy
Hold
Analyst Count
3
6
Target Price
$32.00
★ $35.60
AVG Volume (30 Days)
1.0M
★ 1.4M
Earning Date
05-08-2026
05-12-2026
Dividend Yield
N/A
★ 2.74%
EPS Growth
★ N/A
N/A
EPS
N/A
★ 3.26
Revenue
$123,672,000.00
★ $2,898,426,000.00
Revenue This Year
N/A
$4.57
Revenue Next Year
$2.45
$1.12
P/E Ratio
$72.42
★ $9.28
Revenue Growth
★ 63.54
1.91
52 Week Low
$7.09
$27.15
52 Week High
$25.77
$44.44

Technical Indicators

Market Signals
Indicator
GLUE
CRI
Relative Strength Index (RSI) 29.33 43.14
Support Level N/A $28.86
Resistance Level $15.00 $39.16
Average True Range (ATR) 0.65 1.24
MACD -0.01 0.27
Stochastic Oscillator 10.56 46.30

Price Performance

Historical Comparison
GLUE
CRI

About GLUE Monte Rosa Therapeutics Inc.

Monte Rosa Therapeutics Inc is a clinical-stage biotechnology company that specializes in developing molecular glue degraders (MGDs), a class of small molecule drugs that leverage the body's natural protein destruction mechanisms to selectively degrade therapeutically-relevant proteins. Utilizing the QuEEN platform, the company employ artificial intelligence and proprietary experimental tools to identify target proteins for degradation by MGDs. The company has three programs in clinical development: MRT-6160, a VAV1-directed MGD for immune-mediated diseases; MRT-8102, a NEK7-directed MGD for inflammatory diseases driven by IL-6, and the NLRP3 inflammasome; and MRT-2359, a GSPT1-directed MGD for metastatic castration resistant prostate cancer (mCRPC).

About CRI Carter's Inc.

Carter's Inc makes apparel for babies and children under brand names including Carter's and OshKosh B'gosh. It sells its products through a multi-channel business model, which includes retail stores, eCommerce, and wholesale sales channels, as well as retail omnichannel capabilities in the United States and Canada, which enables it to reach a broad range of consumers around the world. The company operates in three segments; U.S. Retail, U.S. Wholesale, and International. The majority of revenue is derived from U.S. Wholesale segment. The company predominantly sources products through contract manufacturers in Asia. It has multiple distribution centers in the U.S., in addition to distribution centers in Canada and Asia that serve international customers.

Share on Social Networks: